On July 8, 2022 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022 (Press release, Aileron Therapeutics, JUL 8, 2022, View Source [SID1234616558]). Management will be available for in-person meetings at the conference on Tuesday, July 12, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fireside chat will be available under the Investors and Media section of Aileron’s website at View Source A replay of the webcast will be archived on Aileron’s website for 30 days following the event.

On July 8, 2022 AbbVie (NYSE: ABBV) reported that it will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens (Press release, AbbVie, JUL 8, 2022, View Source [SID1234616557]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 8, 2022 Herantis Pharma Plc reported that has appointed Antti Vuolanto (born 1975) as CEO as of 22July2022 (Press release, Herantis Pharma, JUL 8, 2022, View Source,c3598918 [SID1234616555]). Frans Wuite will continue as interim CEO of Herantis Pharma Plc until 21July2022 and as Member of the Board also thereafter.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Antti Vuolanto has acted as the Chief Operating Officer of Herantis Pharma Plc since 2018. Vuolanto graduated as Doctor of Science in Technology at Aalto University, Finland in 2004 in biochemistry and bioprocess technology. He has vast experience in biological drug development, gene therapy products, in-vitro diagnostics, and bioinformatics.

"The Board of Directors commenced the CEO recruitment process in January this year. I am very pleased that, after careful evaluation, we found an internal successor within the company who is well equipped to take over the role of CEO. As a result of his management position in the company, Antti Vuolanto has strong experience and knowledge of Herantis’ business and strategic development, as well as due to his background, expertise in the company’s field of business, research, and product development. Antti has also demonstrated his commitment to the company and its development over the past few years. We thank Frans Wuite for his contribution as interim CEO of Herantis and wish Antti all the best in his new future role," says Timo Veromaa, Chairman of the Board of Herantis.

"It has been an honour to be closely involved in the development of Herantis and the company’s strategy over the last few years and to participate in the important work Herantis is doing in developing disease modifying therapies for Parkinson’s Disease. In my new role, I am able to utilize my knowledge of Herantis’ industry, business and strategic development, and I am excited about the opportunity to participate in Herantis’ next phases in a new role as CEO. I thank the Board of Directors of Herantis for the trust it has shown," says Antti Vuolanto.

On July 8, 2022 Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, reported that the company plans to release its second quarter 2022 financial results after the close of the U.S. financial markets on August 2, 2022 (Press release, Exact Sciences, JUL 8, 2022, View Source [SID1234616553]). Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Second quarter 2022 webcast & conference call details

An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 800-770-2030 domestically or +1 647-362-9199 internationally. The access code for the replay of the call is 4437608. The webcast, conference call, and replay are open to all interested parties.

On July 8, 2022 GlyTherix reported that it has commenced an exciting new collaboration with the GastroEsophageal Malignancies Investigator Network Initiative (GEMINI) to test its Miltuximab monoclonal antibody therapies in gastroesophageal cancers (Press release, Glytherix, JUL 8, 2022, View Source [SID1234616534]). GEMINI, backed by the Torrey Coast Foundation, is a multi-institution collaboration of 22 scientific and clinical investigators dedicated to developing innovative new strategies to treat gastroesophageal malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Sandra Ryeom, Associate Professor in the Division of Surgical Sciences in the Department of Surgery at Columbia University Irving Medical Center and the Scientific Director of GEMINI said, "GEMINI was created to accelerate the clinical trials of new therapies for gastroesophageal malignancies. We have established a network of preclinical and clinical investigators, with expertise in pre-clinical drug screening using in vitro and in vivo models, together with clinical investigators who have led Phase I clinical trials using targeted therapies in combination with immunotherapy and chemotherapy. We have exciting early data about GPC-1 expression in gastroesophageal malignancies and we look forward to testing GlyTherix’s therapies in our models".

Dr Brad Walsh said "GEMINI is an outstanding example of scientific and clinical collaboration to accelerate novel treatments into the clinic. Our Miltuximab therapy has proven safe in our First-in-Human clinical trial and we are looking forward to establishing its efficacy in the treatment of solid tumors. Gastroesophageal cancer is a significant unmet need and we hope that the preclinical data we obtain from this collaboration will provide the data to progress Miltuximab into clinical trials for these patients".